Crs Cytokine Release Syndrome clinical trials

Explore recruiting crs cytokine release syndrome clinical trials.

Recruiting crs cytokine release syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Crs Cytokine Release Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)

Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in patients with CD19+ acute lymphoid leukemia resistant or refractory to therapy

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Belgium, France, Italy, Germany, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Randomized Phase Ib/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

Spain, Denmark, France, Germany, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Crs Cytokine Release Syndrome trials by city

Crs Cytokine Release Syndrome in Toronto Crs Cytokine Release Syndrome in Vancouver Crs Cytokine Release Syndrome in Montreal Crs Cytokine Release Syndrome in Calgary Crs Cytokine Release Syndrome in Edmonton Crs Cytokine Release Syndrome in Ottawa Crs Cytokine Release Syndrome in Winnipeg Crs Cytokine Release Syndrome in Quebec City Crs Cytokine Release Syndrome in Hamilton Crs Cytokine Release Syndrome in Kitchener Crs Cytokine Release Syndrome in London Crs Cytokine Release Syndrome in Halifax Crs Cytokine Release Syndrome in New York Crs Cytokine Release Syndrome in Los Angeles Crs Cytokine Release Syndrome in Chicago Crs Cytokine Release Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease